4.4 Review

Gout and hyperuricemia in young people

期刊

CURRENT OPINION IN RHEUMATOLOGY
卷 23, 期 2, 页码 156-160

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0b013e3283432d35

关键词

transporter; urate deposition; uric acid

向作者/读者索取更多资源

Purpose of review Although gout and hyperuricemia have received considerable attention recently, there is limited information on the two conditions in young people. The molecular mechanisms of hyperuricemia have been investigated extensively in recent years, with this knowledge providing new insights and a better understanding of the precocious onset of gout and hyperuricemia. Recent findings Serum uric acid levels are higher in the younger generation compared with the older generation. A proportion of gout and hyperuricemia in childhood is due to inborn errors in purine metabolism. Extensive investigation has demonstrated genetic polymorphisms in the urate transporter associated with hyperuricemia and gout. Whether or not polymorphisms affect the onset of gout and hyperuricemia in young people is unclear. Uric acid levels in childhood have also been shown to correlate with the development of the metabolic syndrome. Summary Elevations in serum uric acid levels in childhood are often associated with other diseases and allied conditions. Hyperuricemia in young individuals is often a marker of the metabolic syndrome. Gout is not common in childhood compared with adulthood, and careful consideration of inborn errors of metabolism should be considered in these cases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Rheumatology

Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis

Eiichi Tanaka, Yutaka Kawahito, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yuko Kaneko, Hiroya Tamai, Yohei Seto, Akio Morinobu, Takahiko Sugihara, Atsuko Murashima, Masayo Kojima, Masaaki Mori, Hiromu Ito, Toshihisa Kojima, Yasumori Sobue, Keiichiro Nishida, Isao Matsushita, Takeo Nakayama, Hisashi Yamanaka, Masayoshi Harigai

Summary: The systematic review of 20 randomized controlled trials showed that biosimilars and reference bDMARDs were equally effective and safe for managing rheumatoid arthritis.

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis

Takahiko Sugihara, Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Yohei Seto, Toshihisa Kojima, Hiromu Ito, Masataka Kohno, Takeo Nakayama, Yasumori Sobue, Keiichiro Nishida, Isao Matsushita, Atsuko Murashima, Masaaki Mori, Eiichi Tanaka, Shintaro Hirata, Mitsumasa Kishimoto, Hisashi Yamanaka, Masayo Kojima, Masayoshi Harigai

Summary: This study aims to provide an evidence base for developing CPG for the management of rheumatoid arthritis in older adults, by conducting a systematic literature review and assessing the quality of evidence, yielding conclusions on the efficacy and safety of different drug treatments for older RA patients.

MODERN RHEUMATOLOGY (2022)

Article Endocrinology & Metabolism

Vitamin D deficiency is a risk factor for new fractures in Japanese postmenopausal women with rheumatoid arthritis: results from the IORRA cohort study

Masanori Nakayama, Takefumi Furuya, Eisuke Inoue, Eiichi Tanaka, Katsunori Ikari, Hisashi Yamanaka, Masayoshi Harigai

Summary: This study found that vitamin D deficiency is a significant risk factor for new fractures in Japanese female patients over the age of 50 with rheumatoid arthritis, suggesting that screening for serum 25(OH)D levels could potentially reduce the risk of fractures.

ARCHIVES OF OSTEOPOROSIS (2021)

Article Rheumatology

Factors associated with frailty in Japanese patients with rheumatoid arthritis: results from the Institute of Rheumatology Rheumatoid Arthritis cohort study

Takefumi Furuya, Koei Oh, Katsunori Ikari, Eisuke Inoue, Eiichi Tanaka, Hisashi Yamanaka, Masayoshi Harigai

Summary: In this study of 3290 Japanese patients with RA, 16.7% were categorized as frail, 62.7% as prefrail, and 20.6% as robust. Factors such as BMI (both overweight and underweight), DAS28, J-HAQ, EQ-5D, NSAID use, and MTX nonuse were significantly associated with frailty.

CLINICAL RHEUMATOLOGY (2022)

Article Rheumatology

Effectiveness and safety of subcutaneous abatacept in biologic-naive RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study)

Naoto Tamura, Takanori Azuma, Kenta Misaki, Rei Yamaguchi, Fuminori Hirano, Eiji Sugiyama, Daisuke Kanai, Yohko Murakawa, Motohiro Oribe, Takahito Kimata, Kazutoshi Aoki, Tomoko Sugiura, Koji Takasugi, Yuya Takakubo, Yasuyuki Tomita, Takeo Isozaki, Toshihiro Nanki, Naooki Katsuyama, Takanori Kuroiwa, Hideto Oshikawa, Motohide Kaneko, Hiroshi Fujinaga, Kiwamu Saito, Eiichi Tanaka, Eisuke Inoue, Yuri Yoshizawa, Shigeru Matsumoto, Hisashi Yamanaka, Masayoshi Harigai

Summary: This study aimed to evaluate the effectiveness and safety of abatacept in biologic-naive rheumatoid arthritis patients with moderate disease activity. The results showed that abatacept significantly improved disease activity, physical disability, and quality of life over 52 weeks. The incidence of adverse events was relatively high.

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study

Yoshiya Tanaka, Ayako Yamaguchi, Toshiaki Miyamoto, Kazuhide Tanimura, Hideyuki Iwai, Yuko Kaneko, Tsutomu Takeuchi, Koichi Amano, Naoki Iwamoto, Atsushi Kawakami, Miho Murakami, Norihiro Nishimoto, Tatsuya Atsumi, Takayuki Sumida, Koichiro Ohmura, Tsuneyo Mimori, Hisashi Yamanaka, Keishi Fujio, Yoshihisa Fujino, Kazuyoshi Saito, Kazuhisa Nakano, Shintaro Hirata, Shingo Nakayamada

Summary: In patients with rheumatoid arthritis who achieved sustained remission, continuing treatment, dose reduction, or discontinuation of methotrexate and dose reduction of biologic disease-modifying antirheumatic drugs (bDMARDs) achieved comparable disease control after one year. Subsequent de-escalation of methotrexate had no impact on disease control but decreased adverse events in year two.

RHEUMATOLOGY (2022)

Article Rheumatology

Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication

Hiromu Ito, Keiichiro Nishida, Toshihisa Kojima, Isao Matsushita, Masayo Kojima, Shintaro Hirata, Yuko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Masaaki Mori, Akio Morinobu, Atsuko Murashima, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Takeo Nakayama, Hisashi Yamanaka, Yutaka Kawahito, Masayoshi Harigai

Summary: This study aimed to update the clinical practice guidelines for the management of rheumatoid arthritis (RA) in Japan and develop an algorithm for non-drug and surgical treatments. The guidelines were updated using the Grading of Recommendations, Assessment, Development, and Evaluation method, and recommendations were developed based on 19 clinical questions regarding non-drug and surgical treatments. The study also created an original algorithm for the treatment of RA.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: Results from cross-sectional study in the IORRA cohort

Eiichi Tanaka, Eisuke Inoue, Mai Abe, Kumiko Saka, Eri Sugano, Moeko Ochiai, Rei Yamaguchi, Katsunori Ikari, Hisashi Yamanaka, Masayoshi Harigai

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication

Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Hiromu Ito, Toshihisa Kojima, Isao Matsushita, Keiichiro Nishida, Masaaki Mori, Atsuko Murashima, Hisashi Yamanaka, Takeo Nakayama, Masayo Kojima, Masayoshi Harigai

Summary: The Japan College of Rheumatology has updated the clinical practice guidelines for rheumatoid arthritis, providing a useful tool for rheumatologists, healthcare professionals, and patients to make shared decisions in various clinical situations.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis

Hisashi Yamanaka, Yoshiya Tanaka, Toshihiko Hibino, Gopalakrishnan Unmesh, Chirag Shah, Dhananjay Bakhle, Dimitris Stefanidis

Summary: YLB113 biosimilar demonstrated long-term safety and sustained efficacy in patients with rheumatoid arthritis. In a post-hoc analysis, patients treated with YLB113 experienced significantly lower incidence of injection-site reactions and injection-site erythema compared with the reference product.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Multidisciplinary Sciences

Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data

Eiichi Tanaka, Eisuke Inoue, Ayako Shoji, Jonas Nilsson, Christos Papagiannopoulos, Devender Dhanda, Yuri Yoshizawa, Mai Abe, Kumiko Saka, Eri Sugano, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Katsunori Ikari, Hisashi Yamanaka, Masayoshi Harigai

Summary: This study investigated the cost-effectiveness of abatacept as first-line therapy for Japanese RA patients. The results showed that abatacept as first-line therapy had a favorable cost-effectiveness profile, leading to cost savings for Japanese healthcare payers.

PLOS ONE (2022)

Article Rheumatology

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

Claudia A. Salinas, Anthony Louder, Jennifer Polinski, Tancy C. Zhang, Hannah Bower, Syd Phillips, Yufei Song, Emaan Rashidi, Rafia Bosan, Hsiu-Ching Chang, Nicole Foster, Bernice Gershenson, Hisashi Yamanaka, Mitsumasa Kishimoto, Yoshiya Tanaka, Peter Fischer, Baojin Zhu, Douglas Faries, Xiaodan Mai, Brett T. Doherty, Angela Grelaud, Nicolas H. Thurin, Johan Askling, Walter Deberdt

Summary: This study aimed to evaluate the safety of baricitinib compared to tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients. The results showed an increased risk of venous thromboembolism (VTE) with baricitinib compared to TNFi treatment. Although the risk was slightly higher for major adverse cardiovascular events (MACE) and serious infection, the point estimates varied.

RHEUMATOLOGY AND THERAPY (2023)

Article Rheumatology

Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naive to or switched from biologics

Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, Shiro Ohshima, Makoto Inoue, Yutaka Yoshioka, Hisashi Yamanaka

Summary: The post-marketing surveillance study evaluated the safety and efficacy of CT-P13, the first biosimilar of IFX, in real-world settings. CT-P13 showed excellent effectiveness as first-line therapy and clinical improvement in patients who switched from IFX or other bDMARDs. CT-P13 could be a cost-effective alternative to IFX in the treatment of rheumatoid arthritis.

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids

Rei Yamaguchi, Eiichi Tanaka, Ayako Nakajima, Eisuke Inoue, Mai Abe, Eri Sugano, Naohiro Sugitani, Kumiko Saka, Moeko Ochiai, Yoko Higuchi, Naoki Sugimoto, Katsunori Ikari, Hisashi Yamanaka, Masayoshi Harigai

Summary: In the biologics era, risk factors for herpes zoster in rheumatoid arthritis patients include age, Health Assessment Questionnaire score, methotrexate use, and biologic use, while corticosteroid use and doses were decreasing.

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort

Eri Sugano, Eiichi Tanaka, Eisuke Inoue, Ryoko Sakai, Mai Abe, Kumiko Saka, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Yoko Higuchi, Naoki Sugimoto, Katsunori Ikari, Ayako Nakajima, Hisashi Yamanaka, Masayoshi Harigai

Summary: Few rheumatoid arthritis patients met the inclusion criteria of RCTs in clinical settings. There was a difference in the efficacy/effectiveness of bDMARDs between RCTs and clinical practice.

MODERN RHEUMATOLOGY (2022)

暂无数据